L-Threonine

L-Threonine is one of the nine amino acids classified as essential in humans, meaning it cannot be synthesized endogenously and must be obtained from dietary protein ^[1]. Structurally it is a polar amino acid bearing a hydroxyl group on its side chain, which lets it participate in protein O-glycosylation and phosphorylation; it is abundant in animal proteins such as meat, dairy and eggs, and in legumes, nuts and soy ^[1]. Beyond serving as a building block for protein synthesis, threonine is a precursor for glycine and, indirectly, one-carbon metabolism, and it is a major constituent of mucins and immunoglobulins ^[1].

The metabolism of threonine differs by species and by age. In adult humans the threonine dehydrogenase pathway, which converts threonine to 2-amino-3-ketobutyrate and onward to glycine and acetyl-CoA, is a relatively minor route, accounting for only roughly 7 to 11 percent of threonine catabolism; the human threonine dehydrogenase gene is in fact an expressed pseudogene, so the enzyme is far less active in people than in rodents ^[2]. The larger share of threonine is instead catabolized by threonine dehydratase to 2-oxobutyrate. This is why the "threonine as a glycine source" story, while real biochemically, is more prominent in infants and in animals than in adult humans ^[2].

A well-documented role for threonine is in the gastrointestinal tract. The intestine retains a large fraction of dietary threonine on its first pass and uses it heavily for the synthesis of mucins, the heavily O-glycosylated, threonine-rich glycoproteins that form the protective mucus layer of the gut, so threonine is central to intestinal mucosal integrity and barrier function ^[3]. Studies in piglets show that mucin synthesis is acutely sensitive to luminal threonine supply, with restriction reducing mucosal protein and mucin production, which underlies interest in threonine for gut health ^[4]. Much of this evidence, however, comes from young or growing animal models rather than healthy adult humans.

Threonine has also been studied as an antispastic agent, on the rationale that it can raise central nervous system glycine, an inhibitory neurotransmitter in the spinal cord. Early pilot work suggested a benefit in human spasticity ^[5], and a randomized crossover trial in multiple sclerosis using 7.5 g per day found a measurable reduction in signs of spasticity on examination, without symptomatic improvement noticed by patients and with no meaningful side effects; notably, serum and cerebrospinal fluid threonine rose but glycine levels did not change ^[6]. A double-blind, placebo-controlled crossover study in spinal spasticity at 6 g per day likewise reported a modest but statistically significant antispastic effect ^[7]. Across these trials the effect is consistently described as small and of limited clinical value, and threonine is not an established therapy.

L-Threonine is a normal dietary amino acid with a strong safety record at intakes near or somewhat above what food provides. In the spasticity trials, doses of 6 to 7.5 g/day were taken for weeks with no side effects or toxic effects identified, which is reassuring. Very high isolated amino-acid loads can theoretically cause GI upset or shift amino-acid balance, and anyone with liver or kidney impairment or an inborn error of amino-acid metabolism should be cautious with concentrated single amino acids. It is not a substitute for medical treatment of any condition, and pregnant or breastfeeding people should stick to dietary sources unless a clinician advises otherwise.

Threonine is an essential amino acid consumed in gram quantities from ordinary dietary protein, and no clinically significant drug interaction has been documented for it as a supplement. Where it appears on a product label carrying an interactions section, that label is generally a parenteral amino acid solution, and the cautions there belong to the mixture and the route rather than to threonine itself.

Two points are worth stating plainly as theoretical rather than observed. Large amino acid loads compete for intestinal and blood-brain-barrier transport with levodopa, which is why protein timing matters in Parkinson disease; the principal competitors there are the large neutral amino acids such as leucine, phenylalanine and tyrosine, and threonine is not among the main ones. And any amino acid load adds a nitrogen burden that is relevant in advanced hepatic or renal impairment, which is a metabolic consideration rather than a drug interaction.

The honest summary is that there is very little to report here, and claims to the contrary are usually borrowed from the amino acid class as a whole.

Checking a whole stack? Run it through interactions + stacks.